We are live on ! Find out more
JANX icon

Janux Therapeutics
JANX

160 hedge funds and large institutions have $2.07B invested in Janux Therapeutics in 2024 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 56 increasing their positions, 49 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

19% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 27

14% more repeat investments, than reductions

Existing positions increased: 56 | Existing positions reduced: 49

11% more capital invested

Capital invested by funds: $1.87B → $2.07B (+$199M)

3% more funds holding

Funds holding: 155 → 160 (+5)

1.21% more ownership

Funds ownership: 86.26% → 87.46% (+1.2%)

86% less call options, than puts

Call options by funds: $4.14M | Put options by funds: $29.8M

Holders
160
Holders Change
+5
Holders Change %
+3.23%
% of All Funds
2.3%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.04%
New
32
Increased
56
Reduced
49
Closed
27
Calls
$4.14M
Puts
$29.8M
Net Calls
-$25.6M
Net Calls Change
-$25.3M

Top Buyers

1
WP
Woodline Partners
California
+$56.5M
2
PBA
Paradigm Biocapital Advisors
New York
+$36.4M
3
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$31.4M
4
NNPTE
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne
Poland
+$20.5M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$12.4M

Top Sellers

1
O
OrbiMed
New York
-$74.9M
2
Citadel Advisors
Citadel Advisors
Florida
-$23.8M
3
BI
BVF Inc
California
-$18.5M
4
SC
Samlyn Capital
New York
-$13.6M
5
APM
Avidity Partners Management
Texas
-$12.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$416M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$355M +$2.05M +47,075 +0.6%
Janus Henderson Group
3
Janus Henderson Group
United Kingdom
$115M +$31.4M +721,563 +40%
BlackRock
4
BlackRock
New York
$110M +$3.42M +78,629 +3%
PBA
5
Paradigm Biocapital Advisors
New York
$109M +$36.4M +836,122 +53%
Adage Capital Partners
6
Adage Capital Partners
Massachusetts
$94.3M -$11M -252,896 -11%
Vanguard Group
7
Vanguard Group
Pennsylvania
$84M +$12.4M +286,172 +18%
WP
8
Woodline Partners
California
$72.7M +$56.5M +1,299,438 +432%
EC
9
EcoR1 Capital
California
$66.8M – – –
State Street
10
State Street
Massachusetts
$61.8M -$1.74M -40,056 -3%
O
11
OrbiMed
New York
$57.2M -$74.9M -1,721,262 -58%
CAM
12
Cormorant Asset Management
Massachusetts
$47.7M – – –
Citadel Advisors
13
Citadel Advisors
Florida
$45.9M -$23.8M -547,348 -35%
LGM
14
Logos Global Management
California
$45.4M +$10.9M +250,000 +33%
Lord, Abbett & Co
15
Lord, Abbett & Co
New Jersey
$32M +$38K +874 +0.1%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$30.1M +$1.67M +38,490 +6%
APM
17
Avidity Partners Management
Texas
$25.5M -$12.1M -278,219 -33%
VPC
18
Vestal Point Capital
New York
$22M -$10.4M -240,000 -33%
NNPTE
19
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne
Poland
$21.4M +$20.5M +471,736 New
Point72 Asset Management
20
Point72 Asset Management
Connecticut
$18M +$11.3M +259,445 +190%
Goldman Sachs
21
Goldman Sachs
New York
$14.3M -$1.26M -28,937 -8%
Northern Trust
22
Northern Trust
Illinois
$12.1M +$3.14M +72,125 +37%
Charles Schwab
23
Charles Schwab
California
$10.6M +$6.82M +156,675 +202%
PM
24
Prosight Management
Texas
$9.31M +$8.92M +205,000 New
Alyeska Investment Group
25
Alyeska Investment Group
Illinois
$9.23M +$165K +3,800 +2%
1
2 3 4 5

JANX Hedge Fund Activity: Q3 2024 in Review

160 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Janux Therapeutics (JANX) for Q3 2024, worth a combined $2.07B — up 11% from $1.87B a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new JANX positions and 27 closed out — a net gain of 5 holders — while 56 added to existing stakes and 49 trimmed.

The largest buyer was Woodline Partners, adding an estimated $56.5M. The largest seller was OrbiMed, cutting an estimated $74.9M.

  • 160 institutional investors held Janux Therapeutics (JANX) as of Q3 2024, up from 155 in Q2 2024.
  • Funds reported $2.07B of Janux Therapeutics stock for Q3 2024, up 11% quarter-over-quarter.
  • 32 funds opened new Janux Therapeutics positions in Q3 2024 and 27 closed out, a net change of +5 holders.
  • The largest Janux Therapeutics buyer in Q3 2024 was Woodline Partners, an estimated $56.5M added.
  • The largest Janux Therapeutics seller in Q3 2024 was OrbiMed, an estimated $74.9M sold.

Based on aggregated 13F filings for Q3 2024.